Want to see AU:IMM full AI Analyst Report?
IMM Stock Chart & Stats
AU$0.07
-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.07
-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.47
Previous CloseN/A
Volume844.76K
Average Volume (3M)4.11M
Market Cap
AU$84.00M
Enterprise ValueAU$4.57M
Total Cash (Recent Filing)AU$99.13M
Total Debt (Recent Filing)AU$2.16M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,473,721,300
10 Day Avg. Volume7,757,821
30 Day Avg. Volume4,106,545
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.43
Price to Sales (P/S)69.27
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$5.78M
Bulls Say, Bears Say
Bulls Say
LAG‑3 Platform And Diversified PipelineOwning a LAG-3–based platform with multiple clinical candidates provides durable strategic optionality. Multiple programs reduce binary risk from any single trial, support partnering/licensing opportunities, and align with long-term immuno‑oncology demand, sustaining R&D relevance over many quarters.
Conservative Leverage / Strong Equity PositionLow leverage and a healthy equity ratio give the company structural financial flexibility. For a clinical‑stage firm this reduces near‑term insolvency risk, permits prioritization of trials or partnerships, and makes future financing or collaborations less pressured by debt covenants.
Improving Free Cash Flow GrowthNotable improvement in free cash flow growth, even from negative levels, suggests the company is beginning to better align cash usage with operations. Sustained improvement reduces dilution risk over time and increases optionality for funding development via partnerships rather than only equity.
Bears Say
Persistent Negative MarginsConsistent negative gross, EBITDA and net margins indicate the business has structural unprofitability at current stages. For a clinical-stage biotech this means extended reliance on financing until commercialization, making long‑term shareholder returns dependent on successful trials or value‑accretive partnerships.
Negative Operating And Free Cash Flow LevelsMaterial negative operating and free cash flows are a durable constraint: they necessitate external capital or partner funding to sustain trials. This limits autonomy, increases dilution or sublicensing risk, and can delay development timelines if funding terms deteriorate.
Pre-commercial Funding DependenceBeing pre-commercial means revenues depend on collaborations, milestone/licensing payments, and equity raises. Such dependence creates structural execution and funding risk: milestone timing is uncertain and equity financing dilutes shareholders, affecting capital allocation over many quarters.
Immutep Ltd News
IMM FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest share price was AU$0.03 and its highest was AU$0.47 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is AU$84.00M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 61 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Feb 24, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of -AU$0.028 by -AU$0.002.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Overvalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,473,721,300 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of -AU$0.028. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in AU:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IMM Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.33%
12-Months-Change
Fundamentals
Return on Equity
-69.20%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Technical Analysis
Imugene
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Radiopharm Theranostics Limited
―
Options Prices
Currently, No data available
---